Delving into the Latest Updates on Nedaplatin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(glycolato-O,O')diammineplatinum(II), CDGP, Nedaplatin (JAN/INN)

+ [11]

Target

DNA

Action

inhibitors

Mechanism

DNA inhibitors(DNA inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [2]

Active Indication

NeoplasmsBladder CancerEsophageal Carcinoma+ [6]

Inactive Indication-

Originator Organization

Nichi-Iko Pharmaceutical Co., Ltd.

Active Organization

Nichi-Iko Pharmaceutical Co., Ltd.Simcere Zaiming Pharmaceutical Co., Ltd.

Shionogi & Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (30 Jun 1995),

Bladder CancerEsophageal CarcinomaHead and Neck Neoplasms+ [5]

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC2H8N2O3Pt

InChIKeyGYAVMUDJCHAASE-UHFFFAOYSA-M

CAS Registry95734-82-0

This study is a prospective, open-label, multi-center phase III study; patients with untreated stage IIIA to stage IVB head and neck squamous cell carcinoma (including oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, and laryngeal cancer) who meet the inclusion criteria are randomized 1:1 and given pembrolizumab 200 mg d1+ chemotherapy for 2 cycles (experimental group), 2 cycles of chemotherapy (control group), and then stratified according to the patient's condition. If the imaging evaluation after neoadjuvant treatment is (complete response, CR), adjuvant radiotherapy will be given; if the imaging evaluation is (partial response, PR) or (stable disease, SD), surgery (within 2 weeks) will be performed, followed by standard treatment. The main research hypothesis of this study: pembrolizumab combined with standard chemotherapy can significantly improve the rate of pathological complete response (pCR) compared with standard chemotherapy.

Start Date01 May 2023

Sponsor / Collaborator

Beijing Tongren Hospital

100 Clinical Results associated with Nedaplatin

Login to view more data

100 Translational Medicine associated with Nedaplatin

Login to view more data

100 Patents (Medical) associated with Nedaplatin

Login to view more data

1,547

Literatures (Medical) associated with Nedaplatin

01 Feb 2025·International Journal of Surgical Pathology

Whole-Exome Sequencing Identifies Germline BLM Mutation in Ovarian Hepatoid Adenocarcinoma with Favorable Response to Niraparib and Anlotinib Combination Therapy—A Case Report and Literature Review

Review

Author: Wang, Ping ; Zhang, Xiaofang ; Yi, Tianjin ; Cao, Yidan ; Xu, Lian ; Lin, Xiaojuan ; Ye, Pengfei ; Cheng, Yan

Hepatoid adenocarcinoma of the ovary represents a rare and malignant extrahepatic tumor that shares morphological and immunophenotypic similarities with hepatocellular carcinoma. Due to the ambiguous histomorphology and aggressive behavior, the diagnosis and management of hepatoid adenocarcinoma of the ovary present unique challenges. Here, we present a 67-year-old woman with massive ascites and disseminated peritoneal implants at initial diagnosis. She was treated with six cycles of neoadjuvant therapy (albumin-bound paclitaxel + nedaplatin + bevacizumab) and a debulking surgery, followed by eight cycles of postoperative adjuvant therapy (albumin-bound paclitaxel + carboplatin + bevacizumab). Elaborate pathology workup found significant involvement of angiogenesis in the tumor and confirmed the diagnosis via immunohistochemistry. Further molecular characterization of the tumor by whole-exome sequencing (WES) revealed a novel heterozygous germline mutation (NM_000057.2, c.1290_1291delinsATCAGGCCTCCATAG, p.Y430fs1) in gene BLM, likely pathogenic, suggesting a potential candidate for Poly (ADP-ribose) polymerase (PARP) inhibitors. For the maintenance therapy, she received a combination of the PARP inhibitor niraparib and the antiangiogenic anlotinib. As of now, the patient has achieved a partial response, with no apparent evidence of disease progression observed nearly 30 months. Our study sheds light on the WES-based profiling in rare cancers to screen for any treatable targets with otherwise no standard therapeutic options. The promising results with the niraparib–anlotinib combination suggest its potential as a maintenance therapy option for hepatoid adenocarcinoma of the ovary, which warrants validation in future larger cohort.

01 Jan 2025·Journal of Gastroenterology

Definitive-dose adjuvant radiotherapy following endoscopic submucosal dissection for superficial esophageal cancer

Article

Author: Murata, Toshiki ; Watanabe, Kenta ; Shinozaki, Tetsugaku ; Iijima, Katsunori ; Sugawara, Daichi ; Mori, Naoko ; Takagi, Noriko ; Wada, Yuki ; Kumagai, Satoshi ; Matsuhashi, Tamotsu

BACKGROUNDProphylactic chemoradiation therapy (CRT) using 40-41.4 Gy post-endoscopic submucosal dissection (ESD) for clinical T1N0M0 esophageal cancer reportedly yields favorable outcomes. However, it cannot completely prevent locoregional lymph node (LN) metastases. We retrospectively analyzed outcomes and adverse events associated with our dose-escalated treatment regimen (definitive-dose radiotherapy [RT] of 50-61.2 Gy, with/without chemotherapy) for these patients, and predictors of progression-free survival (PFS) and overall survival (OS).METHODSBetween 2006 and 2018, 44 consecutive patients (42 men and 2 women; median age, 70 years) who underwent definitive-dose RT post-ESD and had a pathological depth of the muscularis mucosa with lymphovascular invasion (LVI) or the upper-middle submucosal third at our institution were included. We excluded patients who could not obtain a margin-free resection by ESD. If feasible, systemic chemotherapy with 5-fluorouracil plus high- or low-dose cisplatin or nedaplatin was administered concurrently.RESULTSFive-year PFS, OS, and disease-specific survival rates were 78.8%, 88.4%, and 97.7%, respectively. Six metachronous esophagus (14%), two locoregional LN within the irradiated area with a prophylactic dose of 41.4 Gy (5%), and two locoregional LN plus liver (5%) recurrences occurred. No LN recurrence occurred within the definitive dose of ≥ 50 Gy in the irradiated area. Metachronous esophageal recurrence involved areas receiving ≥ 50 Gy. Univariate and multivariate analyses revealed that age was an independent prognostic factor for both PFS and OS.CONCLUSIONSDefinitive-dose RT/CRT post-ESD could provide favorable locoregional LN control and PFS/OS regardless of patient characteristics, including pathological findings and chemotherapy regimen/course, except for age. These results need to be interpreted carefully given several limitations, therefore, definitive-dose RT/CRT should be conducted with caution in clinical practice until high-quality prospective clinical trials evaluating the effectiveness and safety.

01 Dec 2024·Applied Organometallic Chemistry

Comparison of In Vitro and In Vivo Biological Screening of Nano‐Palladium (II) and Platinum (II)‐Based Compounds With DFT and Molecular Docking Study

Author: Aboutabl, Mohamed A. ; Hosny, Wafaa M. ; Khalf‐Alla, Perihan A. ; Fayed, Dalia B. ; Hassan, Safaa S.

ABSTRACTWithin the current challenges in medicinal chemistry, the creation of novel and improved therapeutic agents stands out. 2‐Cyano‐3‐(thiophen‐2‐yl)prop‐2‐enethioamide (CTPTA) ligand was complexed with palladium (II) and platinum (II) ions within the nanoscale with the molecular formula [M (CTPTA)Cl2]. H2O. The CTPTA ligand and its complexes were characterized by elemental analysis, UV–Vis spectra, FTIR, mass spectra, TGA, magnetic measurement, and the molar conductance technique. Analysis with a scanning electron microscope (SEM) revealed that the nanostructure dimension of both complexes is predominantly between 10 and 30 nm. The CTPTA ligand functions as a bidentate ligand, utilizing thione sulfur, and cyanide nitrogen atoms. Density functional theory was employed to analyze the geometric structure properties of the CTPTA ligand and its complexes. Natural population (NPA) and Mulliken population (MPA) methods were used to calculate the charge distribution. The cytotoxic impact results of all compounds on human liver cancer (HepG2) cell line were satisfactory. The ligand and its complexes were also tested against gram‐negative and gram‐positive bacteria in vitro. The findings of the molecular docking study supported the cytotoxicity and antibacterial effects. The antioxidant and anti‐inflammation activities of synthesized palladium (II) and platinum (II) complexes had a great spectrum of activity. The preclinical pharmacokinetic studies on albino rats revealed that the newly studied complexes achieved excellent antitumor results. This was clear in the investigated parameters, especially the amelioration of AFP levels, liver weight, oxidative stress, and lobular hepatic architecture injury.

100 Deals associated with Nedaplatin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01416	Nedaplatin	L01XA	DB13145

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Neoplasms	Japan	Shionogi & Co., Ltd.	05 Sep 1995
Bladder Cancer	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1995
Esophageal Carcinoma	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1995
Head and Neck Neoplasms	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1995
Non-Small Cell Lung Cancer	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1995
Ovarian Cancer	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1995
Small Cell Lung Cancer	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1995
Testicular Neoplasms	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1995
Uterine Cervical Cancer	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1995

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06010212 (ASCO_GI2025) Manual	Phase 2	Advanced Esophageal Squamous Cell Carcinoma First line	11	Fruquintinib + camrelizumab +paclitaxel liposome + nedaplatin	(sqflsyofiy) = mhdzlcqvky czjgeodcvi (exvqhiaorm, 42.1 - 99.6) View more	Positive	23 Jan 2025
NCT04834206 (ASCO 12023 \| ASCO 22023) Manual	Phase 2	Nasopharyngeal Carcinoma First line	32	intensity-modulated radiotherapy+nedaplatin+docetaxel+5-fluorouracil	(bqknpunybz) = vrfwbwqrbt dnovfdahdp (kynoobrjcg ) View more	Positive	31 May 2023
ChiCTR2100049693 (ASCO 12023 \| ASCO 22023) Manual	Phase 2	Esophageal Carcinoma Neoadjuvant	27	anlotinib+tislelizumab+paclitaxel liposome+nedaplatin	(uhirxwmgut) = zptckrkbcx zdofzilyua (slzrlnwhvs, 61 - 94.5)	-	31 May 2023
ESMO_IO2022	Not Applicable	Advanced Esophageal Squamous Cell Carcinoma First line	35	Pembrolizumab + Albumin-bound paclitaxel + Nedaplatin	(qkcdnzkppa) = 3 patients (8.6%) qeephzwgzs (aiecqregww )	Positive	08 Dec 2022
ChiCTR1800017108 (Pubmed) Manual	Phase 3	Uterine Cervical Cancer	160	radiotherapy+Nedaplatin	(qaoeohxufv) = nqccojwtra myjkgpnbfm (tsbktpysuo ) View more	Non-inferior	19 Aug 2022
ChiCTR1800017108 (Pubmed) Manual	Phase 3	Uterine Cervical Cancer	160	radiotherapy+Cisplatin	(qaoeohxufv) = eezdiypyfw myjkgpnbfm (tsbktpysuo ) View more	Non-inferior	19 Aug 2022
NCT02607592 (NACA, ASCO2022) Manual	Phase 3	Advanced Lung Adenocarcinoma First line EGFR Negative \| ALK Negative	218	Pemetrexed+Nedaplatin	(qjplfkxmda) = odeoicdjqz bdawialneb (lugbxljwnh, 5.25 - 8.49) View more	Non-inferior	02 Jun 2022
NCT02607592 (NACA, ASCO2022) Manual	Phase 3		218	Pemetrexed+Cisplatin	(qjplfkxmda) = unjjsijraf bdawialneb (lugbxljwnh, 4.57 - 6.50) View more	Non-inferior	02 Jun 2022
NCT03057106 (CCTG BR34 \| CCTG BR.34, CTgov)	Phase 2	Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	301	Tremelimumab+Durvalumab (Durvalumab and Tremelimumab)	(mbrnqlnewx) = skgksuehfn szfbpytzmw (gtkkrgluuq, xdecjyoxfd - zdoikdeklf) View more	-	09 Feb 2022
NCT03057106 (CCTG BR34 \| CCTG BR.34, CTgov)	Phase 2	Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	301	Tremelimumab+Lobaplatin+Cisplatin,+Durvalumab+Nedaplatin (Platinum Based Chemotherapy + Durvalumab + Tremelimumab)	(mbrnqlnewx) = cuigdhpgom szfbpytzmw (gtkkrgluuq, upindrrptx - magvkokbgn) View more	-	09 Feb 2022
ChiCTR2100046355 (ESMO_IO2021)	Phase 2	Locally Advanced Esophageal Squamous Cell Carcinoma First line	86	Camrelizumab + Paclitaxel + Nedaplatin	(qnaalfoije) = iktwzdqunh ppxdqttzop (ywwstxtazn ) View more	-	09 Dec 2021
ChiCTR2100046355 (SITC 12021 \| SITC 22021) Manual	Phase 2	Esophageal Squamous Cell Carcinoma First line	83	paclitaxel+nedaplatin+Camrelizumab	(xgdxucvida) = reduction of redblood cell (21%), anemia (18%), hypomagnesemia (18%), fatigue(14%), thrombocytopenia (11%), hand-foot skin reaction (8.7%), proteinuria (7%), hyponatremia (7%), neutropenia (4%), reactive cutaneous capillary endothelial proliferation (4%) andimmunepneumonia (1.4%). xiiuhsjbzb (lvcuqbfhom )	Positive	25 Sep 2021
CSCO2021	Not Applicable	Squamous Cell Carcinoma of Head and Neck \| Gastrointestinal Neoplasms	18	尼妥珠单抗+奈达铂+白蛋白紫杉醇方案	(mpslleiwma) = sewzwfhiut wtfadhcmel (fwhyceosdl )	-	25 Sep 2021